ArticleActa biomaterialia2025
Proteomic insights into vaginal mesh complications and treatment targets.
Article in Acta biomaterialia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Profiling the T cell response to polypropylene mesh in a non-human primate sacrocolpopexy model.Biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo characterize differences in vaginal proteomic profiles among women with mesh exposure, mesh-related pain, and controls.
methods10 well-integrated mesh samples (removed incidentally or normally incorporated distant from complication), 10 mesh exposure samples, 10 mesh-pain samples and 10 control vaginal biopsies of participants without mesh from a Mesh and Pelvic Floor Tissue Biorepository were analyzed. Differentially expressed protein analysis, gene ontology enrichment, clinical covariate modeling and a hypothesis-driven assessment of 100 a priori specified proteins were performed.
resultsParticipant age of well-integrated mesh specimens (62 ± 13 years) was similar to complication samples (exposure 52 ± 7, pain 49 ± 14 years) but older than controls (42 ± 6 years). Mean BMI (28 ± 6 kg/m
conclusionsEven well-integrated polypropylene mesh dramatically alters the local environment. Pain and exposure complications progress through epithelial remodeling, dysregulated extracellular matrix, and fibrosis pathways similarly regardless of clinical risk factors, supporting that constructive matrix remodeling therapies and neutrophil targeting may be useful therapeutics. STATEMENT OF SIGNIFICANCE: Polypropylene mesh is used in urogynecologic surgery to improve the durability and reduce invasiveness of surgical repairs, however it is associated with a high complication rate. In order to improve the response to polypropylene mesh implanted on the vagina and to design better materials, we must understand the pathways through which these complications develop. This proteomic analysis showed that inflammation, disordered extracellular and epithelial remodeling, apoptosis and fibrosis were the most different between complications and controls, both validating prior mechanistic studies and providing potential therapeutic targets, including matrix degradation protein inhibitors and neutrophil pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.